1. Home
  2. NRSN vs HHS Comparison

NRSN vs HHS Comparison

Compare NRSN & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRSN
  • HHS
  • Stock Information
  • Founded
  • NRSN 2017
  • HHS 1923
  • Country
  • NRSN Israel
  • HHS United States
  • Employees
  • NRSN N/A
  • HHS N/A
  • Industry
  • NRSN Biotechnology: Pharmaceutical Preparations
  • HHS Advertising
  • Sector
  • NRSN Health Care
  • HHS Consumer Discretionary
  • Exchange
  • NRSN Nasdaq
  • HHS Nasdaq
  • Market Cap
  • NRSN 26.0M
  • HHS 27.3M
  • IPO Year
  • NRSN 2021
  • HHS N/A
  • Fundamental
  • Price
  • NRSN $1.18
  • HHS $3.71
  • Analyst Decision
  • NRSN Buy
  • HHS
  • Analyst Count
  • NRSN 2
  • HHS 0
  • Target Price
  • NRSN $14.00
  • HHS N/A
  • AVG Volume (30 Days)
  • NRSN 1.4M
  • HHS 21.1K
  • Earning Date
  • NRSN 09-17-2025
  • HHS 11-13-2025
  • Dividend Yield
  • NRSN N/A
  • HHS N/A
  • EPS Growth
  • NRSN N/A
  • HHS N/A
  • EPS
  • NRSN N/A
  • HHS N/A
  • Revenue
  • NRSN N/A
  • HHS $174,951,000.00
  • Revenue This Year
  • NRSN N/A
  • HHS $6.54
  • Revenue Next Year
  • NRSN N/A
  • HHS N/A
  • P/E Ratio
  • NRSN N/A
  • HHS N/A
  • Revenue Growth
  • NRSN N/A
  • HHS N/A
  • 52 Week Low
  • NRSN $0.80
  • HHS $3.06
  • 52 Week High
  • NRSN $2.60
  • HHS $7.72
  • Technical
  • Relative Strength Index (RSI)
  • NRSN 46.42
  • HHS 53.28
  • Support Level
  • NRSN $1.14
  • HHS $3.67
  • Resistance Level
  • NRSN $1.28
  • HHS $3.83
  • Average True Range (ATR)
  • NRSN 0.15
  • HHS 0.10
  • MACD
  • NRSN 0.03
  • HHS 0.01
  • Stochastic Oscillator
  • NRSN 22.33
  • HHS 67.57

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: